- Home
- IREN vs ARQT Comparison
IREN vs ARQT Comparison
Compare IREN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IREN | ARQT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 2.6B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IREN | ARQT |
|---|---|---|
| Price | $62.88 | $21.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $62.50 | $34.00 |
| AVG Volume (30 Days) | ★ 44.7M | 2.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 234.48 | 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $501,023,000.00 | $376,072,000.00 |
| Revenue This Year | $104.58 | $34.85 |
| Revenue Next Year | $200.20 | $29.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 167.65 | 91.34 |
| 52 Week Low | $8.32 | $12.72 |
| 52 Week High | $76.87 | $31.77 |
Technical Indicators
Market Signals| Indicator | IREN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 45.51 |
| Support Level | $36.43 | $21.12 |
| Resistance Level | $64.60 | $21.84 |
| Average True Range (ATR) | 4.74 | 0.99 |
| MACD | 0.67 | 0.11 |
| Stochastic Oscillator | 75.36 | 58.95 |
Price Performance
Historical ComparisonAbout IREN Iris Energy Limited
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.